drugset / Trial / NCT01810653

A Study to Compare the Effect of Transipeg 2.95 g or Forlax Junior 4 g in Children With Constipation

NCT01810653

Phase 4 Completed 97 enrolled Bayer
RandomizedParallel-groupTriple-blindTreatment

Summary

The study design combines a long-term safety and a dose range determination objective. The first 8 weeks of the study were primarily intended for the dose range determination, while the later visits were used for the comparison of long-term safety between the groups.

Timeline

Start
2006-04
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Polyethylene Glycols Unknown

Indications